Tildren for Horses 500 mg, 30 mL vial
Prescription Item
Oops! Something went wrong. Please try again.
Tildren is a prescription medication formulated to help horses control symptoms associated with navicular syndrome. This degenerative condition typically causes pain in the heel of the horse’s front feet, where the navicular bone is located. Horses can experience pain from changes in the bones, tendons, ligaments and bursa—the joint structures that are filled with fluid. This pain can result in lameness, which causes the horse to move abnormally by overcompensating for the affected area. Tildren helps to restore balance to the bone remodeling process, which replaces old bone tissue with new tissue.
UsesTildren is indicated for the control of clinical signs associated with navicular syndrome in horses. Navicular syndrome is the most common cause of chronic forelimb lameness in performance horses. It is a degenerative process instigated by mechanical forces.
Possible Side EffectsDo not use in horses with impaired renal function or with a history of renal disease. Bisphosphonates are excreted by the kidney; therefore, conditions causing renal impairment may increase plasma bisphosphonate concentrations resulting in an increased risk for adverse reactions. Do not use in horses with known hypersensitivity to tiludronate disodium or to mannitol.
Drug & Food InteractionsNSAIDs should not be used concurrently with Tildren. Concurrent use of NSAIDs with Tildren may increase the risk of renal toxicity and acute renal failure.
Precautions
NSAIDs should not be used concurrently with Tildren. Concurrent use of NSAIDs with Tildren may increase the risk of renal toxicity and acute renal failure. The safe use of Tildren has not been evaluated in horses less than 4 years of age. Bisphosphonates should not be used in pregnant or lactating mares, or mares intended for breeding.
-
Item Number157432
-
For Use WithHorses
-
Generic NameTiludronate Disodium
-
Common Brand Name(s)Tildren
-
Administration FormInjection
-
Product FormInjectable
-
Health ConditionNavicular Syndrome, Muscle Lameness
-
Drug TypeAntihistamine
Each vial of Tildren contains: 500 mg of Tiludronic acid (as Tiludronate Disodium), 250 mg Mannitol USP (excipient).
A single dose of Tildren should be administered as an intravenous infusion at a dose of 1 mg/kg (0.45 mg/lb). The infusion should be administered slowly and evenly over 90 minutes to minimize the risk of adverse reactions. Maximum effect may not occur until 2 months post-treatment.
Storage InstructionsSterile powder (not reconstituted): Store at controlled room temperature 68-77° F (20-25° C). After preparation, the infusion should be administered either within 2 hours of preparation, or it can be stored for up to 24 hours under refrigeration at 36-46° F (2-8° C) and protected from light.
What is Navicular Syndrome?
Navicular syndrome is the most common cause of chronic forelimb lameness in performance horses. Horses suffering from navicular syndrome feel pain in the heel, caused by degenerative bone lesions of the navicular bone. Clinical signs can vary, but are typically associated with a gait change or lameness, often aggravated when walking on hard ground or trotting circles.
How does Tildren work?
The active ingredient in Tildren is tiludronate disodium, a bisphosphate that achieves its effect by regulating osteoclasts in areas of excessive activity. Following IV infusion, Tildren travels through the blood stream and binds to the mineral matrix of the bone. The acidity of the remodeling environment causes the release of Tildren® from the bone matrix to the resorption space. This leads to improved bone remodeling, decreased mineral loss and alleviation of pain induced by abnormal osteolysis.
What does Treatment with Tildren look like?
Tildren (tiludronate disodium) will be administered to your horse through an intravenous infusion. It is administered over a 90-minute period. Tildren is most effective when used in conjunction with corrective farriery and a controlled exercise program. Visit with your veterinarian to learn more about management and care after Tildren has been given.
What is the efficacy of Tildren?
Tildren (tiludronate disodium) given at 1mg/kg IV, in conjunction with corrective shoeing, proved to be more effective in controlling clinical signs associated with navicular syndrome when evaluated at two months post-treatment compared to corrective shoeing alone.
Customer Reviews
Be the first to recommend this product.
Write a Review